To acquire 23andMe’s Personal Genome Service, Total Health and Research Services business lines, and its Biobank and ...

Regeneron Pharmaceuticals logged a 0.4% change during today's morning session, and is now trading at a price of $571.03 per share. The S&P 500 index moved -2.0%. REGN's trading volume is 167,455 ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment ...

Re­gen­eron can’t dodge a law­suit al­leg­ing it un­law­ful­ly in­flat­ed Medicare re­im­burse­ments for its eye drug Eylea and de­fraud­ed the US out of hun­dreds of mil­lions … ...

Regeneron Pharmaceuticals Inc. REGN shares are trading higher on Wednesday, recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results.

Costco doesn't take the quality of Kirkland Signature items for granted—even wildly popular fan-favorites can be yanked off the shelves at any time to be reformulated or repackaged, and tweaked until ...

La Jolla’s push to secede from the city of San Diego can continue, after the successful appeal of a San Diego County decision to reject some signatures on petitions backing the effort.

Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to emerge as a profitable commercial operation and establish a narrow moat.

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...

Regeneron Pharmaceuticals (REGN) shares sank when the biopharma firm's earnings and revenue missed forecasts as sales of its blockbuster eye treatment, Eylea, were weaker than anticipated.